Lumipulse® G Total Tau
Immunoreaction cartridge for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of total Tau in human cerebrospinal fluid (CSF).
This CSF biomarker is intended to be used as an aid for diagnosis in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.
Product number 230312
Product number 230329
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Other documents
FileWhitepaper - Biomarkers for Alzheimers disease.pdf (pdf, 148.72 kb)FileFileFilePractical guide for lumbar puncture.pdf (pdf, 263.94 kb)Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Influence of automation on Aβ1-42/Aβ1-40 ratio and its use
Automation is an important step in the direction of more standardization as it limits the number of manual handling steps and therefore minimizes...
Mar 16, 2020
Comparison of Aβ1-42/Aβ1-40 ratio with other ratios
CSF Aβ1-42/Aβ1-40 is a tool to normalize values of patients with different amyloid levels, as other ratios might be seen more as interpretation tools...
Mar 2, 2020
How to work with Aβ1-42/Aβ1-40 ratio
One cause of discordant results can be the preanalytical conditions, e.g. when laboratories use tubes that bind certain proteins. Aβ1-42 adsorption is...
Feb 5, 2020
-
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Related products
-
Product inquiry
